Clinical Report: Privosegtor Receives Breakthrough Drug Designation

Overview

Oculis Holding AG's Privosegtor has received FDA breakthrough therapy designation for optic neuritis. The designation is based on promising results from the phase 2 ACUITY trial, which demonstrated significant visual acuity improvements and neuroprotective effects.

Background

Optic neuritis is a rare neuro-ophthalmic condition that can lead to permanent vision loss, making effective treatment crucial. Current management primarily involves high-dose corticosteroids, but there is a need for neuroprotective therapies that can preserve visual function and retinal structures. Privosegtor represents a potential advancement in the treatment landscape for optic neuropathies.

Data Highlights

Key Findings

• Privosegtor is designed to cross the blood-brain and retinal barriers.
• In the ACUITY trial, patients receiving Privosegtor showed an average gain of 18 letters on the ETDRS chart at 3 months.
• The treatment preserved retinal and optic nerve structure and reduced neurofilament release.
• Common adverse events included headache and acne, with no serious drug-related events reported.
• The PIONEER program includes 3 pivotal trials to support registration for optic neuritis and nonarteritic anterior ischemic optic neuropathy.

Clinical Implications

The breakthrough designation for Privosegtor highlights its potential as a novel neuroprotective therapy for optic neuritis, which may improve patient outcomes. Clinicians should consider the implications of this therapy in the context of current treatment paradigms and ongoing clinical trials.

Conclusion

Privosegtor's breakthrough therapy designation marks a significant step forward in the treatment of optic neuritis, offering hope for improved visual outcomes in affected patients. Continued research and clinical trials will be essential to validate its efficacy and safety.

References

1. Oculis Holding AG, Oculis, 2025 -- Privosegtor Receives Breakthrough Drug Designation
2. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial - PubMed, 2018
3. FDA Approves Soliris (Eculizumab) for Neuromyelitis Optica Spectrum Disorder | Drug Topics, 2024
4. The ASCO Post — FDA Grants Breakthrough Therapy Designation to MPDL3280A for Non–Small Cell Lung Cancer
5. The ASCO Post — FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma
6. The ASCO Post — FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
7. The ASCO Post — Crizotinib Receives Breakthrough Therapy Designation for ROS1-Positive NSCLC
8. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial - PubMed
9. FDA Approves Soliris (Eculizumab) for Neuromyelitis Optica Spectrum Disorder | Drug Topics
10. Study Assessments and Endpoints